Board Change • May 20
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 7 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). CFO, Company Secretary & Executive Director James Desler is the most experienced director on the board, commencing their role in 2006. Independent Non-Executive Chairman Martin Gouldstone was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. お知らせ • Jun 07
ValiRx plc, Annual General Meeting, Jun 30, 2025 ValiRx plc, Annual General Meeting, Jun 30, 2025. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom お知らせ • Mar 27
ValiRx plc Announces Directorate Changes and Formation of New Advisory Board ValiRx Plc announced the resignation of Adrian de Courcey from its Board of Directors and that Cathy Tralau-Stewart has agreed with the Board to transition to a role as Non-Executive Director of the Company. The Company also announced the formation of its new Advisory Board which will replace its current Scientific Advisory Board. Cathy Tralau-Stewart, Chief Scientific Officer and Director of the Company, has agreed with the Board to transition to a role as Non-Executive Director of the Company with immediate effect. Cathy will be appointed as Chair of the new Advisory Board set up to deliver Scientific, Commercial and Strategic Advice to the Company. Adrian de Courcey has informed the Board that he has resigned as Non-Executive Director of the Company with immediate effect, to focus on other opportunities. During her tenure as the fractional CSO, Cathy has been instrumental in developing ValiRx's pipeline strategy, identifying, reviewing and advising on a series of Evaluation and In-licensing options. Cathy brings a wealth of experience in drug development as well as industry contacts and recognition which ValiRx wishes to retain. During Adrian's tenure as a ValiRx Non-Executive Director, he has helped the Company navigate a major strategic and organisational overhaul with the new management team to achieve significant operational efficiencies and reduce cash burn. These changes at the Board level form part of implementing a significant restructure and reduction in headcount across the Company As part of the restructure, the Company has hired a new, full time, Director of Research (non-board role), Michelle Barnard, who brings over 10 years' experience as a Senior Scientist specialising in Oncology Biology at Cancer Research Horizons and in Drug Discovery at the University of Graz prior. The Inaphaea team will also be supported by a specialist technician. These changes are expected to reduce annual costs by approximately £200,000. New Advisory Board: ValiRx has also assembled a range of experts to establish its new Advisory Board ("AB"). The initial members of the AB, in addition to Cathy Tralau-Stewart as chair, will comprise: Dr Heather Wilson Robles, a clinical oncologist and former President of the Veterinary Cancer Society, specialising in veterinary medicine is based at United Veterinary Care and Ethos Discovery based in Washington DC US. Dr Simon Wheeler, a former member of Novartis Ventures tasked with finding Veterinary medicine investments and now an Independent Animal Health and Veterinary Consultant. The AB brings a combination of scientific and commercial expertise as well as contacts within the industry. The AB also brings a balance of human and veterinary medicine expertise as the company explore opportunities to leverage the preclinical data for earlier access to the veterinary market in addition to the primary focus on the human market. Board Change • Oct 23
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 7 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). CFO, Company Secretary & Executive Director James Desler is the most experienced director on the board, commencing their role in 2006. Independent Non-Executive Chairman Martin Gouldstone was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. お知らせ • Oct 18
ValiRx plc Announces Resignation of Martin Lampshire as A Non-Executive Director ValiRx plc announced the resignation of Martin Lampshire as a Non-Executive Director of the Company, effective from 18 October 2024. Martin has decided to step down from the Board of ValiRx to concentrate on his other commitments. During Martin's four year tenure as a ValiRx Non-Executive Director, he has made significant contributions to the development of the strategy and helped the Company build relationships with various City stakeholders.